Finch Therapeutics Inc. is developing an oral alternative to fecal microbial transplant that it believes entails less biology risk than more advanced oral candidates, with more targeted delivery than full microbiome transplants delivered via enema.
Takeda is paying Finch Therapeutics $10 million upfront for exclusive, global rights to develop and commercialize the latter’s inflammatory bowel disease (IBD) candidate, FIN-524, together with rights to follow-on products for IBD indications.
Back when Mark Smith was working on his PhD at MIT about 6 years ago, his girlfriend’s cousin was infected with C.diff. After 7 reoccurrences following treatment with vancomycin, though, the cousin finally beat it by getting a fecal transplant, with his roommate as the donor.
Finch Therapeutics, Inc., a microbiome therapeutics company, and OpenBiome, a leading public stool bank, today announced a collaboration to develop FIN-403, an orally administered microbial therapy for approval by U.S. Food and Drug Administration (FDA) in recurrent C. difficile infections.
"Finch Therapeutics is designing products comprised of pure cultures of microbes that will serve the same purposes of fecal microbiotas transplantation while also being safer and more scalable." -- Forbes